SCHEMBL1437239

SCHEMBL1437239

CCOC(=O)c1nc(CC(C)(C)C)n(-c2cc(Cl)ccc2C)c1-c1cc(Cl)ccc1OC

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 4/20 0.39
GABRB2 P47870 4/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA1 P14867 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRA6 Q16445 1/20 0.39
MDM2 Q00987 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 3/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
LMNA P02545 3/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1438216 0.91 MDM2 (0.49) MDM2GAATP53
SCHEMBL1436894 0.90 MDM2 (0.40) MDM2MAPTGAATP53
SCHEMBL1437413 0.88 LMNA (0.46) MDM2MAPTGAALMNATP53
SCHEMBL9894878 0.84 MDM2 (0.58) GABRA2GABRB2MDM2MAPTGAA
SCHEMBL9893616 0.84 MAPT (0.49) GABRA2GABRB2GABRG2GABRB3GABRA5
SCHEMBL9894027 0.84 MDM2 (0.58) GABRA2GABRB2GABRG2GABRB3GABRA5
SCHEMBL1437158 0.83 MDM2 (0.47) GABRA2GABRB2GABRG2GABRB3GABRA5
SCHEMBL9894149 0.82 GABRA2 (0.42) GABRA2GABRB2GABRG2GABRB3GABRA5
SCHEMBL1437100 0.82 MDM2 (0.46) GABRA2GABRB2MDM2MAPTGAA
SCHEMBL9893799 0.81 MDM2 (0.60) GABRA2GABRB2GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 GABRA2 4293/4885GABRB2 4278/4885GABRG2 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.